Teda Biotechnology (08189) announces a positive profit alert, expecting a mid-term net profit attributable to shareholders of approximately 7 million to 10 million yuan, achieving a turnaround from loss to profit year-on-year.

Zhuhai Finance APP news, Teda Biotech (08189) announced that for the six months ending June 30, 2026, the group expects to achieve: revenue of approximately RMB 290 million to RMB 300 million, an increase of about 28% to 33% compared to revenue of about RMB 226 million for the six months ending June 30, 2025 (the same period last year); and a net profit attributable to shareholders of approximately RMB 7 million to RMB 10 million, compared to a net loss attributable to shareholders of about RMB 6 million in the same period last year, reflecting an increase of approximately 209% to 256%, thus achieving a turnaround from loss to profit.